Medications

An FDA approval for an autoinjector of a biosimilar ustekinumab can make treatment easier to administer and may increase availability or affordability of a drug used to treat Crohn’s disease and ulcerative colitis....

Cure8 could only read part of this source from hcplive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease and Medications.

An FDA approval of an autoinjector for ustekinumab may make self‑injection easier and more convenient for people with Crohn’s disease or ulcerative colitis who use this biologic. Changes in delivery format can also...

New phase IIb trial results suggest an anti‑TL1A antibody (duvakitug) produced measurable benefit in both Crohn’s disease and ulcerative colitis, which could lead to a new treatment option if later phase III trials...

People with ulcerative colitis taking etrasimod may have higher drug levels if they have certain CYP2C9 genotypes or significant liver impairment; dose adjustments could be needed to avoid increased exposure.

Patients with UC who fail both anti-TNF and JAK inhibitor therapies have limited options. This report suggests tacrolimus can be used as a short-term bridge or in combination to reach another maintenance drug, with many...

The review explains why many patients still fail current therapies and summarizes promising new research directions (microRNA, microbiome therapies, stromal cell approaches) that could change treatment strategies.

Reliable, high-throughput lab methods are a prerequisite for therapeutic drug monitoring (TDM). For people with IBD on JAK inhibitors, validated assays can enable exposure measurement needed for future precision dosing...

In young children, enteric infections can mimic or coexist with VEO‑IBD and change imaging and clinical findings; recognizing both can affect diagnosis and treatment choices.

Updated FDA prescribing information affects safety monitoring and counseling for people with ulcerative colitis who take mesalamine, including children meeting the weight threshold. The label highlights kidney monitoring...

Prednisone is a commonly used systemic steroid for short-term control of IBD flares; label updates affect dosing, warnings, and official approved uses that patients and clinicians rely on.

This label update restates safety information for ROWASA (a mesalamine rectal formulation) used for distal ulcerative colitis. Patients with IBD should be aware of potential serious hypersensitivity reactions, kidney and...

This update is important because tofacitinib is a JAK inhibitor approved for adults with moderately to severely active ulcerative colitis after inadequate response to TNF blockers, and the label includes major safety...

This label update affects people with IBD because tofacitinib is an approved oral JAK inhibitor for moderately to severely active ulcerative colitis and the label highlights important safety risks (infections, mortality,...

This is an FDA drug-label record for ABRILADA (an adalimumab product). It confirms that ABRILADA is approved for treating moderately to severely active Crohn’s disease (adults and children 6+) and ulcerative colitis...

The FDA label defines who may be prescribed tofacitinib and highlights important safety warnings (serious infections, increased mortality signal, and malignancy risk) relevant to people with IBD and other autoimmune...

Market growth and industry activity can affect drug availability, prices, and the pace of new treatments or diagnostics reaching patients. Increased investment in biomarkers and targeted therapies may lead to better...

People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.

Early-phase trials test whether new treatments are safe and show biological activity. This study measures fecal calprotectin, a biomarker of intestinal inflammation, so it could provide early signals about whether ND-12...

People on biologic therapy who lose response often face choices: switch drugs or increase dose. This study shows that escalating doses of infliximab, adalimumab, or vedolizumab frequently led to clinical improvement and...

The paper reports a novel small molecule (CA-23) that directly antagonizes CD28, reducing pathogenic T cell responses in preclinical IBD models and in cells from IBD donors. If validated, this represents a...

If successful, this approach could lower costs and simplify storage/transport of an established IBD antibody (adalimumab) and enable oral delivery, which would be relevant to people with Crohn’s disease or ulcerative...

Because it describes a severe new Crohn’s disease case temporally linked to COVID‑19, patients and clinicians should be aware that persistent or worsening GI symptoms after SARS‑CoV‑2 infection may merit investigation;...

Many people on ustekinumab who lose response wonder whether increasing dosing frequency helps. This prospective study suggests that empiric intensification to every 4 or 6 weeks raised drug levels and was linked with...

Based on the title and source metadata, this appears to be a case report related to Crohn's disease and Complications. The original article is from JAAD case reports.

Patients with ulcerative colitis and PSC face higher risk of pouch inflammation after IPAA. The study reports fewer pouchitis events among the small group who received antibiotics or immunosuppression, which could...

Extraintestinal symptoms such as fatigue and joint pain significantly affect quality of life in Crohn's disease. This review suggests ustekinumab may help reduce fatigue and arthritis/arthralgia more than TNF antagonists...

The study identifies a cellular mechanism (JAK1-STAT6 pathway) by which upadacitinib can lower IL13RA2 — a molecule tied to inflammation and anti-TNF resistance — which could help explain how JAK inhibitors work in IBD...

Hepatitis E can cause elevated liver enzymes in people with IBD on biologics or small molecules. This series found infections were acute and resolved without chronic infection, and advanced therapy could be restarted....

This study highlights changing patterns of IBD presentation and treatment over 26 years in a large Hispanic cohort, which may affect outcomes and access-to-care discussions for Hispanic patients.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from Journal of Crohn's & colitis.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Translational gastroenterology and...

For people hospitalized with acute severe ulcerative colitis, starting a JAK inhibitor together with IV steroids right away (rather than waiting for steroids to fail) could potentially control inflammation sooner and...

This study identifies FUT8, an enzyme that adds core fucose to N-glycans, as a possible new target to reduce pro-inflammatory T-cell responses in IBD. For people with IBD, new mechanisms in preclinical research may...

Ustekinumab is already approved for moderate-to-severe Crohn's disease; this real-world study reports encouraging longer-term clinical, biological, and endoscopic outcomes up to 96 weeks and suggests good treatment...

The review links gut microbiota changes and mucosal immune responses across IBD and IgA nephropathy, suggesting that gut dysbiosis may contribute to systemic immune-driven disease.

Drug levels and how patients reach remission can differ depending on prior biologic use. For families and clinicians managing pediatric Crohn's, this can affect how infliximab dosing and monitoring are interpreted after...

This study reports early-stage lab and mouse evidence for new small molecules that target the JAK2–STAT3 immune signaling pathway, a pathway relevant to inflammation in ulcerative colitis. If findings are confirmed in...

This trial tests a mushroom-derived dietary supplement in people with mild-to-moderate UC or colonic/ileal Crohn's disease, measuring symptoms, fecal biomarkers, and endoscopic activity—outcomes that matter to patients...

This registry will track how people with moderate to severe ulcerative colitis do on risankizumab in routine Japanese clinical practice, which may provide information about real-world remission rates and longer-term...

Children with IBD often wait years for medicines to be approved after adult approvals; this review shows many ongoing paediatric trials for biologics and small molecules that could improve treatment options.

Joint inflammation is a common and impactful extraintestinal issue in IBD; recognizing and treating it appropriately affects symptoms, function, and quality of life.

Cure8 found this source from Journal of pediatric gastroenterology and nutrition, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Risankizumab, and IL-23 inhibitor. Open the...

The study pinpoints OTUD5 as a molecular driver of IFNγ-driven intestinal inflammation and links it to anti-TNFα nonresponse; blocking OTUD5 with a small molecule reduced colitis in mice and in human organoids, which...

The study introduces a novel preclinical therapeutic approach that selectively degrades HDAC6 and reduced inflammation in a mouse model of colitis, suggesting a potential new drug-discovery avenue relevant to ulcerative...

Ustekinumab treats Crohn’s disease and ulcerative colitis; a biosimilar that shows similar pharmacokinetics and safety could expand treatment options and affect availability and cost.

Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Medications. Open the original article for the full details.

Patients and clinicians considering sequencing of advanced UC therapies may care because this study reports differences in how long patients stayed on second-line treatment depending on the order of anti-TNF agents and...